New Three-Drug attack on aggressive breast cancer enters testing
NCT ID NCT06175390
Summary
This study is testing a new combination of two immunotherapy drugs (tiragolumab and atezolizumab) with standard chemotherapy for triple-negative breast cancer. It aims to see if this three-part treatment is safe and more effective at shrinking tumors before surgery for early-stage cancer and at controlling advanced cancer for longer. The trial will enroll 81 women with either newly diagnosed, non-metastatic cancer or with metastatic cancer that has spread.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Curie
Paris, 92210, France
-
Institut Curie
Saint-Cloud, 92210, France
Conditions
Explore the condition pages connected to this study.